Form 4 for ANAB ANAPTYSBIO, INC
Accepted 2026-01-16 00:00:00 ET · period of report 2026-01-15 · accession 0001631486-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-01-16 | 2026-01-15 | ANAB | Marquet Magda | Dir | S - Sale+OE | $48.23 | -11.0K | 9,930 | -53% | -$530.6K |
| D | 2026-01-16 | 2026-01-15 | ANAB | Marquet Magda | Dir | M - OptEx | $26.11 | +11.0K | 20.9K | +111% | +$287.2K |
| D | 2026-01-16 | 2026-01-15 | ANAB | Marquet Magda | Dir | M - OptEx | $0.00 | -11.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-15 | S | D | 9,290 | $48.12 | 11,640 | D | — | — | (F1) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.595 to $48.54 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2026-01-15 | S | D | 1,710 | $48.85 | 9,930 | D | — | — | (F2) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.625 to $48.88 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2026-01-15 | M | A | 11,000 | $26.11 | 20,930 | D | — | — | |
| 4 | Derivative | Stock Option (right to buy) | 2026-01-15 | M | D | 11,000 | $0.00 | 0 | D | $26.11 · — to 2031-01-17 | 11,000 Common Stock | (F4) In addition to the options to purchase shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 70,104 shares of common stock, which options vest according to their terms. (F3) The stock option is fully vested. |